![]() There are concerns that the company's sales growth could slow as the U.S. Like Novavax and other growth stocks, Fastly has been clobbered since mid-February. Since Fastly's network is based on usage, an increase in traffic caused its revenue growth to soar. While the pandemic has been awful for humankind, those of us stuck at home increasingly turned to the internet for work, news, and entertainment. ![]() There's no question that Fastly was one of the key beneficiaries of the coronavirus pandemic. Fastly's network helps to expedite the delivery of content to end users in a secure manner. Patient investors should also dump Dogecoin in favor of fast-paced edge cloud giant company Fastly ( FSLY 0.56%). With the company expected to turn the corner to profitability in 2022 or 2023, all while maintaining a double-digit growth rate, its valuation of roughly two times sales looks downright cheap. These new verticals can help EverQuote maintain a 20%-plus sales growth rate. ![]() Even though auto insurance accounted for $84.5 million (up 25% year over year) of the company's $103.8 million in first-quarter revenue, the $19.3 million generated from life, health, renters, and home insurance was up 41% from the prior-year period. Advertisers are, therefore, getting more bang for their advertising buck.Īnother interesting thing about EverQuote is that it's expanding into new verticals. In other words, rather than tossing money as a print campaign, EverQuote's marketplace consumers are qualified and motivated shoppers. The platform is convenient for users, and it allows insurers to more effectively target their ad dollars. Consumers use its online marketplace to get quotes and comparison shop auto policies, with an estimated one in five ultimately purchasing an auto policy. By the end 2021, the company is forecast to hold close to a 7% share of the $6.5 billion digital ad-spend market.ĮverQuote's foundational growth driver is its auto insurance marketplace. Whereas the entire insurance ad and distribution industry is projected to grow by an annualized rate of 4% through 2024, EverQuote expects digital ad spending on insurance products to grow by 16% annually over the same time frame. But what makes EverQuote such an incredible company is its focus on the fastest-growing channel within the industry: digital advertising. insurance is about as exciting as watching paint dry. In other words, Novavax could be bringing in $4 billion to $6 billion in annual sales from its COVID-19 vaccine, if approved.Īnother stock with the long-term potential to go to the moon is insurance company EverQuote ( EVER -5.53%). This would give Novavax a real shot to become one of a handful of major players in developed countries, as well as in emerging markets. What's more, booster vaccines are almost certainly going to be needed, unless COVID-19 is somehow eradicated. This has some folks wondering if Novavax is going to miss out on the low-hanging fruit in lucrative developed markets.īut here's the thing: Novavax's potential market for its vaccine is global. Why? The answer is that it's delayed its emergency-use authorization filing for NVX-CoV2373 in the U.S., U.K., and Europe from the second quarter to the third quarter, and announced it may not be producing vaccines at full capacity until the fourth quarter. Yet, take a closer look at Novavax's stock chart and you'll see it's lost more than half of its value in under four months. It demonstrated efficacy of 96.4% against the original strain of COVID-19 and 86.3% efficacy against the most prominent variant in the U.K. and produced a vaccine efficacy that was just shy of 90%. The company's experimental vaccine, NVX-CoV2373, was tested in a large-scale trial in the U.K. ![]() First up is clinical-stage drug developer Novavax ( NVAX -5.30%), which looks to be sitting on a treatment capable of billions of dollars in annual sales.Īs you might have guessed, Novavax's claim to fame has to do with its development of a COVID-19 vaccine.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |